Cancer immunotherapy

US9308253B2 · kind B2 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Young Jun Kim · Seojong-myeon, KR
• Drew M. Pardoll · Silver Spring, US
• Juan Fu · Timonium, US

Key dates

• Filing date: Sep 19, 2012
• Grant date: Apr 12, 2016
• Expiry date: Sep 25, 2032

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/876
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

We formulated multiple TLR agonists into GVAX (lethally irradiated tumor cell vaccines engineered to secrete GM-CSF). Specifically, GLA and R848, TLR4 and TLR7/8 agonists found to be safe in patients, were formulated with GVAX (TEGVAX—for TLR agonists enhanced GVAX), and this formulation was effective in producing anti-tumor responses in 3 different preclinical models, including palpable B16. These anti-tumor responses were correlated with increased CD4 and CD8 T-cells that can secrete IFNγ circulating in the tumor microenvironment as well as significantly higher level of p15E specific CTL mediated cell killing in mice treated with TEGVAX in comparison to controls. When combined with anti-PD-1 antibody, TEGVAX was able to induce regression of established B16 tumors.